ArticleFrontiers in aging neuroscience2026
Reduced serum LEFTY2 and disease-dependent biomarker associations in Alzheimer's disease: an exploratory study.
Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reliable blood-based biomarkers are increasingly needed for the detection and monitoring of Alzheimer's disease (AD). Left-right determination factor 2 (LEFTY2) is a secreted protein of the transforming growth factor-β (TGF-β) superfamily. Evidence from AD-related neuronal models suggests that LEFTY2 promotes neuronal survival, attenuates amyloid- and tau-related pathology, and suppresses inflammatory responses, highlighting its potential relevance to AD. However, its clinical significance and relationship with AD-related blood biomarkers remain unclear. In this study, we investigated the association between serum LEFTY2 and and biomarkers associated with amyloid pathology, tau pathology, neuroinflammation, and neurodegeneration in patients with AD and age-matched cognitively normal (CN) controls. Biomarker levels were quantified using enzyme-linked immunosorbent assays. Serum LEFTY2 levels were significantly lower in AD patients than in cognitively normal controls, whereas Amyloid-beta 1-40 (Aβ1-40), phosphorylated tau (pTau) 181 and Neurofilament light chain (NF-L) levels were significantly elevated. Correlation analyses revealed a positive association between LEFTY2 and Aβ1-42 in AD patients, while correlations with biomarkers of tau pathology, inflammation, and neurodegeneration were less consistent. In cognitively normal controls, LEFTY2 was negatively correlated with total tau and positively correlated with TGF-β1. Collectively, these findings indicate that LEFTY2 exhibits distinct associations with AD-related biomarkers in a disease-dependent manner. These exploratory findings provide new insights into the relationships among circulating AD biomarkers and support further investigation of LEFTY2 as a novel candidate blood-based marker in larger prospective cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.